HC

HCW Biologics IncNASDAQ HCWB Stock Report

Last reporting period 31 Mar, 2024

Updated 26 Nov, 2024

Last price

Market cap $B

0.021

Micro

Exchange

XNAS - Nasdaq

HCWB Stock Analysis

HC

Uncovered

HCW Biologics Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-46/100

Low score

Market cap $B

0.021

Dividend yield

Shares outstanding

35.871 B

HCW Biologics Inc. is a biopharmaceutical company. It focuses on discovering and developing immunotherapies designed to improve health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, and autoimmune diseases. The Company uses its TOBI (Tissue factOr-Based fusIon) discovery platform to generate designer, multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is designed to treat the impact of accumulated senescent cells and the senescence-associated secretory phenotype (SASP) factors which they secrete by eliminating senescent cells and reducing SASP factors. HCW9218 is in a clinical trial in patients with advanced pancreatic cancer. HCW9302 is designed to activate and expand regulatory T (Treg) cells to suppress the activity of inflammasome-bearing cells and the inflammatory factors.

View Section: Eyestock Rating